Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001076

Drug Information
NameBuclizine
SynonymsHistabutyzine hydrochloride; Buclizine; DB00354; 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine; 4-23-00-00082 (Beilstein Handbook Reference); 129-74-8; NCI60_002006; C07777; Aphilan R; Buclizine (INN); 87994-02-3; Buclizine [INN:BAN]; 1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine; AC1Q3ND3; UNII-0C94V6X681; Buclifen; CID6729; MolPort-003-845-425; Buclizinum [INN-Latin]; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, dihydrochloride; 82-95-1; 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine; Buclina (TN); Histabutizine; 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine; NSC25141; PIPERAZINE, 1-(p-tert-BUTYLBENZYL)-4-(p-CHLORO-alpha-PHENYLBENZYL)-; AC-15954; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)- (9CI); Buclizinum; Hitabutyzyne; Buclizine dihydrochloride; CHEBI:3205; L000971; AR-1I0822; C28H33ClN2; Buclizine Hydrochloride (*dihydrochloride*); Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-; Buclizine hydrochloride; Buclizina [INN-Spanish]; Buclodin; 1-(4-Tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine; Buclizina; EINECS 201-448-1; Vibazine hydrochloride; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-; Buclizine, hydrochloride; Aphilan-R base; 129-74-8 (di-hydrochloride); Softran; Vibazine; Bucladin; AH 2526; UCB 4445; component of Bucladin-S; component of Softran; LS-110571; Histabutyzine dihydrochloride; Histabutyzine; Buclina; Histabuticine; BRN 0349567; Posdel; D07547; AC1L1N6A
Trade NameMigraleve
CompanyMcNeil Laboratories
IndicationNausea and vomiting
[ICD9: 787, 787.0   ICD10: R11]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-
30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1
-3H3
InChIKeyMOYGZHXDRJNJEP-UHFFFAOYSA-N
Canonical SMILESCC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl    
Therapeutic ClassAntihistamine
CAS NumberCAS 82-95-1
FormulaC28H33ClN2
PubChem Compound IDCID 6729.
PubChem Substance IDSID 9979.
ChEBI3205;
SuperDrug ATC IDR06AE01
SuperDrug CAS ID000082951;
TargetHistamine H1 receptorAntagonist[2]
Ref 1Drug information of Buclizine, 2008 To Reference
Ref 2Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543